Author:
Heudel P.,Ray-Coquard I.,Méeus P.,Treilleux I.,Labidi I.,Trédan O.,Mithieux F.,Racadot S.,Peix M.,Mignotte H.,Bachelot T.,Lauraine E. Pujade,Pautier P.,Guastalla J.-P.
Reference124 articles.
1. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in smallvolume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47: 159–166
2. Lhomme C, Morice P, Planchamp F et al. (2008) [Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer—update. According to the methodology of Standards, Options: Recommendations (SOR)]. Bull Cancer 95: 881–886
3. Angioli R, Plotti F, Palaia I et al. (2008) Update on lymphadenectomy in early and advanced ovarian cancer. Curr Opin Obstet Gynecol 20: 34–39
4. Eisenkop SM, Spirtos NM, Friedman RL et al. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90: 390–396
5. Trimbos JB, Bolis G (1994) Guidelines for surgical staging of ovarian cancer. Obstet Gynecol Surv 49: 814–816